Lineage Cell Therapeutics, Inc.
LCTX
$1.68
$0.074.35%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.05% | 76.43% | 19.42% | 6.19% | -0.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.05% | 76.43% | 19.42% | 6.19% | -0.60% |
| Cost of Revenue | -3.52% | -28.93% | -35.62% | -40.99% | -16.79% |
| Gross Profit | 160.76% | 112.90% | 98.25% | 97.79% | 56.86% |
| SG&A Expenses | 23.96% | 28.74% | 28.38% | 31.94% | -16.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.60% | 10.82% | 5.66% | 2.75% | -17.36% |
| Operating Income | -5.94% | 7.57% | -0.47% | -1.30% | 23.23% |
| Income Before Tax | -236.77% | -68.40% | 31.59% | 20.19% | 19.59% |
| Income Tax Expenses | -- | -- | -- | -- | 100.00% |
| Earnings from Continuing Operations | -236.77% | -68.40% | 31.59% | 13.49% | 13.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -127.69% | -1,050.00% | -69.57% | -285.71% | -204.84% |
| Net Income | -236.42% | -69.14% | 31.49% | 13.39% | 12.81% |
| EBIT | -5.94% | 7.57% | -0.47% | -1.30% | 23.23% |
| EBITDA | -5.98% | 7.61% | -0.96% | -1.75% | 23.66% |
| EPS Basic | -169.28% | -35.07% | 41.64% | 22.83% | 18.44% |
| Normalized Basic EPS | -157.68% | -2.82% | 30.55% | 17.58% | 37.50% |
| EPS Diluted | -169.28% | -35.07% | 41.64% | 22.83% | 18.44% |
| Normalized Diluted EPS | -157.68% | -2.82% | 30.55% | 17.58% | 37.50% |
| Average Basic Shares Outstanding | 25.54% | 22.43% | 19.98% | 15.95% | 7.29% |
| Average Diluted Shares Outstanding | 25.54% | 22.43% | 19.98% | 15.95% | 7.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |